Daily Stock Analysis, IBIO, Ibio Inc, priceseries

Ibio Inc. Daily Stock Analysis
Stock Information
Open
0.17
Close
0.15
High
0.17
Low
0.14
Previous Close
0.17
Daily Price Gain
-0.02
YTD High
1.40
YTD High Date
Aug 20, 2019
YTD Low
0.14
YTD Low Date
Nov 15, 2019
YTD Price Change
-0.63
YTD Gain
-81.09%
52 Week High
1.40
52 Week High Date
Aug 20, 2019
52 Week Low
0.14
52 Week Low Date
Nov 15, 2019
52 Week Price Change
-0.67
52 Week Gain
-82.01%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 13. 2017
3.00
Sep 19. 2017
3.17
4 Trading Days
5.83%
Link
LONG
Dec 22. 2017
1.80
Dec 26. 2017
1.90
1 Trading Days
5.56%
Link
LONG
Feb 28. 2018
2.00
Mar 13. 2018
2.37
9 Trading Days
18.47%
Link
LONG
Jun 8. 2018
1.50
Jun 11. 2018
1.58
1 Trading Days
5.33%
Link
Company Information
Stock Symbol
IBIO
Exchange
NYSE MKT
Company URL
http://www.ibioinc.com
Company Phone
302 355-0650
CEO
Robert B. Kay
Headquarters
Delaware
Business Address
9 INNOVATION WAY, SUITE 100, NEWARK, DE 19711
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001420720
About

iBio, Inc. operates as a biotechnology company which focuses on commercializing its proprietary technology, iBioLaunch and iBioModulator, and developing product candidates derived from these platforms. iBioLaunch is a proprietary, transformative platform technology for development and production of biologics using transient gene expression in hydroponically grown, unmodified green plants. iBioModulator is a proprietary technology platform that is designed to improve the potency and duration of effect of both prophylactic and therapeutic vaccines produced with any recombinant expression technology including iBioLaunch. The company was founded on April 15, 1993 and is headquartered in Newark, DE.

Description

iBio, Inc., a biotechnology company, focuses on commercializing its proprietary plant-based protein expression technologies in the United States and internationally. The company's proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of therapeutic proteins and vaccines; iBioModulator, a technology platform that is designed to enhance the potency and duration of effect of prophylactic and therapeutic vaccines; and iBio Advanced Technologies. Its therapeutic protein product candidates comprise IBIO-CFB03 for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and other fibrotic diseases; C1 esterase inhibitor, a plasma-derived protein; Alpha-Galactosidase, an enzyme replacement product; and Palivizumab, a monoclonal antibody. The company's vaccine candidates include H1N1 Influenza and H5N1 Influenza viral disease vaccines, which have completed Phase I clinical trials; Yellow Fever viral disease vaccine, which is in preclinical stage; Human Papillomavirus therapeutic vaccine; and malaria and hookworm parasitic pathogen vaccines, which are in Phase I clinical trials. Its biodefense product candidates include Anthrax/Plague bacterial disease vaccine; and Anthrax, a monoclonal antibody. The company has a collaboration agreement with Fraunhofer Center for Molecular Biology to perform research and development activities to develop the recombinant form of C1 esterase inhibitor. It also has a collaboration and license agreement with FioCruz for the use of its proprietary technology in connection with the development, manufacture, and commercialization of vaccines; and a license and collaboration agreement with Caliber Biotherapeutics LLC to use its iBioLaunch platform in connection with the development of an undisclosed monoclonal antibody-based therapeutic protein for an oncology indication. iBio, Inc. is based in New York, New York.